NO944917D0 - Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av eggstokkdysgenese, forsinket pubertet eller seksuell infantilisme - Google Patents

Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av eggstokkdysgenese, forsinket pubertet eller seksuell infantilisme

Info

Publication number
NO944917D0
NO944917D0 NO944917A NO944917A NO944917D0 NO 944917 D0 NO944917 D0 NO 944917D0 NO 944917 A NO944917 A NO 944917A NO 944917 A NO944917 A NO 944917A NO 944917 D0 NO944917 D0 NO 944917D0
Authority
NO
Norway
Prior art keywords
phenyl
aroylthiophenes
inhibition
delayed puberty
ovarian dysgenesis
Prior art date
Application number
NO944917A
Other languages
English (en)
Other versions
NO944917L (no
Inventor
Jeffrey Alan Dodge
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944917D0 publication Critical patent/NO944917D0/no
Publication of NO944917L publication Critical patent/NO944917L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
NO944917A 1993-12-21 1994-12-19 Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av ovarial dysgenese, forsinket pubertet eller seksuell infantilisme NO944917L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/170,946 US5451589A (en) 1993-12-21 1993-12-21 Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism

Publications (2)

Publication Number Publication Date
NO944917D0 true NO944917D0 (no) 1994-12-19
NO944917L NO944917L (no) 1995-06-22

Family

ID=22621923

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944917A NO944917L (no) 1993-12-21 1994-12-19 Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av ovarial dysgenese, forsinket pubertet eller seksuell infantilisme

Country Status (19)

Country Link
US (4) US5451589A (no)
EP (1) EP0662325B1 (no)
JP (1) JPH07215867A (no)
KR (1) KR950016733A (no)
CN (1) CN1107702A (no)
AT (1) ATE207748T1 (no)
AU (1) AU8153294A (no)
CA (1) CA2138500A1 (no)
CZ (1) CZ321694A3 (no)
DE (1) DE69428877T2 (no)
DK (1) DK0662325T3 (no)
ES (1) ES2162844T3 (no)
HU (1) HUT71228A (no)
IL (1) IL112049A0 (no)
NO (1) NO944917L (no)
PT (1) PT662325E (no)
RU (1) RU94045272A (no)
SI (1) SI0662325T1 (no)
ZA (1) ZA9410097B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
CA2162586C (en) 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6649645B1 (en) * 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
ES2246234T3 (es) 1999-05-04 2006-02-16 Strakan International Limited Glicosidos de androgenos y actividad androgenica de los mismos.
WO2002034266A1 (en) * 2000-10-25 2002-05-02 Eli Lilly And Company Method for inhibiting cataracts

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
PT662325E (pt) 2002-03-28
SI0662325T1 (en) 2002-06-30
DK0662325T3 (da) 2001-12-03
EP0662325A2 (en) 1995-07-12
HU9403654D0 (en) 1995-02-28
RU94045272A (ru) 1996-10-20
HUT71228A (en) 1995-11-28
US5719165A (en) 1998-02-17
JPH07215867A (ja) 1995-08-15
ES2162844T3 (es) 2002-01-16
CN1107702A (zh) 1995-09-06
US5843962A (en) 1998-12-01
US5760060A (en) 1998-06-02
NO944917L (no) 1995-06-22
US5451589A (en) 1995-09-19
ZA9410097B (en) 1996-06-19
IL112049A0 (en) 1995-03-15
ATE207748T1 (de) 2001-11-15
CZ321694A3 (en) 1995-08-16
KR950016733A (ko) 1995-07-20
EP0662325B1 (en) 2001-10-31
EP0662325A3 (en) 1995-10-11
AU8153294A (en) 1995-06-29
CA2138500A1 (en) 1995-06-22
DE69428877T2 (de) 2002-04-25
DE69428877D1 (de) 2001-12-06

Similar Documents

Publication Publication Date Title
UA26930C2 (uk) Засіб для іhгібуваhhя еhдометріозу
DE69430465D1 (de) Hemmung uteriner Fibrose
DK0659416T3 (da) Inhibering af seborE og acne
DE69412049T2 (de) Hemmung von dysfunctionalen Uterusblutungen
NO944917D0 (no) Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av eggstokkdysgenese, forsinket pubertet eller seksuell infantilisme
NO943873D0 (no) Hemming av bruskdegradering

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application